Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFINE: Apelin and Relaxin in Healthy, Overweight, and Type 2 Diabetes
NCT03449251Phase 2Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Mar 2018
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Apelin, Relaxin in type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Mar 2018; status: active, not recruiting.
02
Drugs
ApelinRelaxin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03449251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449251.